X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Voorraadrapport

Marktkapitalisatie: US$87.5m

X4 Pharmaceuticals Toekomstige groei

Future criteriumcontroles 3/6

X4 Pharmaceuticals's earnings are forecast to decline at 8% per annum while its annual revenue is expected to grow at 54.8% per year. EPS is expected to grow by 4.8% per annum. Return on equity is forecast to be 46.3% in 3 years.

Belangrijke informatie

-8.0%

Groei van de winst

4.8%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroei54.8%
Toekomstig rendement op eigen vermogen46.3%
Dekking van analisten

Good

Laatst bijgewerkt13 Aug 2024

Recente toekomstige groei-updates

Recent updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 02

Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?

Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?

X4 Pharmaceuticals: Upcoming Catalysts

Sep 19

X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%

Jul 20

X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended

Jul 01

X4 Pharma: Late Stage Nanocap Targeting Rare Diseases

Aug 03

Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

Jun 22
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?

X4 Pharmaceuticals EPS misses by $0.44

May 06

How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

Mar 16
How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?

X4 Pharmaceuticals EPS misses by $0.12

Nov 05

Winst- en omzetgroeiprognoses

NasdaqCM:XFOR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026101-77N/AN/A6
12/31/202544-111N/AN/A7
12/31/20246-43N/AN/A7
6/30/2024118-120-112N/A
3/31/2024N/A-129-104-104N/A
12/31/2023N/A-101-97-97N/A
9/30/2023N/A-111-88-88N/A
6/30/2023N/A-131-86-86N/A
3/31/2023N/A-96-83-83N/A
12/31/2022N/A-96-77-77N/A
9/30/2022N/A-103-77-77N/A
6/30/2022N/A-102-72-72N/A
3/31/2022N/A-100-73-73N/A
12/31/2021N/A-103-72-71N/A
9/30/2021N/A-85-70-69N/A
6/30/2021N/A-82-71-69N/A
3/31/2021N/A-78-63-62N/A
12/31/20203-62-60-59N/A
9/30/20203-55-52-51N/A
6/30/20203-55-50-49N/A
3/31/20203-53-53-52N/A
12/31/2019N/A-53-48-48N/A
9/30/2019N/A-55-46-46N/A
6/30/2019N/A-46-40-39N/A
3/31/2019N/A-40-31-31N/A
12/31/2018N/A-36-25-25N/A
9/30/2018N/A-31-23-23N/A
12/31/2017N/A-25N/A-21N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: XFOR's earnings are forecast to decline over the next 3 years (-8% per year).

Winst versus markt: XFOR's earnings are forecast to decline over the next 3 years (-8% per year).

Hoge groeiwinsten: XFOR's earnings are forecast to decline over the next 3 years.

Omzet versus markt: XFOR's revenue (54.8% per year) is forecast to grow faster than the US market (8.9% per year).

Hoge groei-inkomsten: XFOR's revenue (54.8% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: XFOR's Return on Equity is forecast to be very high in 3 years time (46.3%).


Ontdek groeibedrijven